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Introduction
In the process of tumor invasion and metastasis,
damage to the surrounding tissues, such as the extra-
cellular matrix (ECM), the basement membrane and
the vascular walls, plays a key role [1]. To form metas-
tasis, tumor cells invade through the basement mem-
brane barrier in the proteolytic process of the ECM
components [2]. Many proteolytic enzymes are
involved in this process, including matrix metallopro-
teinases (MMPs), cysteine and serine proteases [1].
Matrix metalloproteinases (MMPs), including
MMP-2 and MMP-9, belong to the family of
enzymes which degrade the extracellular matrix, and
facilitate tumor invasion and spread [3,4]. MMPs are
secreted as non-active forms of proenzymes which
have to be activated to exert an effect on the extra-
cellular matrix. Tissue inhibitors of metalloproteinas-
es (TIMPs), produced by the host or tumor cells,
block latent active MMPs and help prevent the inva-
sion of tumor cells [5].
MMPs are assigned on the basis of the in vitro sub-
strate specificity of the respective metalloproteinases
to three groups: collagenases, gelatinases and stre-
omelisins [6,7]. Gelatinases, mainly MMP-2, degrad-
ing the basement membrane components seem to play
a role at the initial stage of tumor invasion, while other
MMPs cooperate at a later stage of the invasion [8].
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MMP-9 (92- kDa, gelatinases, type IV collagenase)
is a member of the family of the MMP genes that dam-
age the ECM through type IV collagen degradation [9]
and promote tumor cell invasion. The expression of
this protein has been observed in tumors of various
organs, including prostate carcinoma, brain carcinoma,
melanoma, lymphoma and pancreatic carcinoma [10-
15]. In renal carcinoma, MMP-9 expression has been
shown to be associated with unfavorable progno-
sis[16]. In gastric carcinoma, this expression is related
to such clinico-pathological factors as TNM staging,
lymphatic invasion and tumor invasion depth [17].
Cathepsin B (Cath B), a member of a large family of
cysteine proteases of the papain type, exhibits a potential
to destroy laminin - a basement membrane protein [18].
High cathepsin B activity has been observed in gastric
carcinoma in comparison to the adjacent normal mucous
membrane. Moreover, the activity of cathepsin B has
been found to increase in tumors metastasizing to lymph
nodes [19]. High levels of cathepsin B have not only
been detected from the tumor [20,21], but also from the
serum and urine of gastric carcinoma patients [22]. A
correlation has been observed between the expression of
cathepsin B and high-grade carcinomas, including breast
carcinoma [23,24], lung carcinoma [25] and colorectal
carcinoma [26]. The expression of cathepsin B in cancer
tissue is related to more aggressive behavior and higher
metastasis potential [27].
The aim of the study was to assess the correlation
of the expression of MMP-9 and cathepsin B in gastric
carcinoma with chosen clinico-pathological parame-
ters and survival time.
Materials and methods
Collection of samples. The study group consisted of 91 chosen
patients with advanced gastric cancer (29 women and 62 men). The
mean age was 62 years (range 30-83). The group of patients were
clinically monitored for a 84 months.
In all cases, specimens were obtained from the main mass of
tumor and metastatic lymph nodes. The specimens were fixed in
10% buffered formaldehyde and embedded in paraffin. Sections, 5
μm thick, were cut and stained with hematoxylin-eosin. 
Immunohistochemistry. The sections were deparaffinized in three
changes of xylene and hydrated through an alcohol series of a
decreasing concentration. For detection of MMP-9 and cathepsin B
proteins, the sections were heated to 95°C for 15 min in citrate
buffer (10 mmol/l) and incubated with 0.5% hydrogen peroxide
solution in methanol for 15 min and with monoclonal antibodies
(NCL-MMP-9, Novocastra Laboratories, dilution 1:40) for all
night at 4°C and cathepsin B (NCL-CATH-B, Novocastra Labora-
tories, dilution 1:40) for 120 minutes in room temperature.
Novostain Super ABC Kit (NCL- ABCm, Novocastra Laboratories
Ltd, UK) was applied as a detection kit. The antigen-antibody com-
plex was visualized by DAB chromogen (S3000, DAKO, Poland). 
Evaluation of samples. Protein expression was assessed using a
semi-quantitative method and defined as follows:
• Low expression- when there was no reaction or less than 30%
of cells in main mass of tumor and lymph node metastasis were
MMP-9 and cathepsin B positive.
• High expression - when more than 30% of cancer cells in main
mass of tumor and lymph node metastasis were MMP-9 and
cathespsin B positive
The percentage of MMP-9 and cathepsin B positive cells was
calculated in 500 cancer cells in each preparation, at magnification
of 400x (by two independent pathologists).
Statistical analysis. Statistical analysis was based on test χ2 and
exact Fisher's test. The p<0.05 was considered statistically signifi-
cant. Multivariate Cox regression analysis was done to evaluate the
5-year overall survival.
Results
Expression of MMP-9 and chosen 
clinico-pathological parameters in main mass
of tumor and in lymph node metastasis 
(Table 1)
High expression of MMP-9 in main mass of tumor
was found in 38 patients and in 22/27 cases of lymph
node involvement. The expression was localized in the
cytoplasm of cancer cells (Fig. 1). Statistical analysis
revealed no correlation of MMP-9 expression in pri-
mary tumor and lymph node metastasis with patients'
gender, tumor location, invasion depth, Lauren's clas-
sification or histological differentiation. MMP-9 in
primary tumor was present in 27/27 (100%) tumors
metastasizing to lymph nodes. 
Expression of cathepsin B and chosen 
clinico-pathological parameters in main mass
of tumor and lymph node invasion 
(Table 2)
The expression of cathepsin B was observed in cellu-
lar cytoplasm (Fig. 2). Statistical analysis showed a
correlation of tumor cathepsin B expression with
lymph node involvement and invasion depth. Howev-
er, such parameters as patients' gender, tumor location,
Lauren's classification and histological differentiation
were not found to correlate with cathepsin B expres-
sion by tumor or metastasis.
Expression of MMP-9 and cath B vs. 
postoperative survival time of patients
In our study, the mean survival time in patients with
high tumor expression of MMP-9 was 84 months, as
compared to those with low expression - 60 months.
Moreover, in the group of high MMP-9 expression, the
mortality rate was increased between the 2nd-10th
month. However, it was not statistically significant
(Fig. 3).
The mean survival time of patients with tumor
cathepsin B expression was approximately 60 months,
being 84 months in cathepsin B-negative group. In the
former group, higher mortality rate was observed
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between the 2nd - 32nd month. In the latter, death rate
was increased at a similar time interval, i.e. between
the 5th-26th month after surgery. The data were not
statistically significant (Fig. 4).
Discussion
The process of metastasizing depends on the activity
of various proteolytic enzymes, mainly proteases. In
this process, cancer cells attach closely to each other,
combine with laminin in the basement membrane, with
thromboplastin or other agents, and in this way local
proteolysis mediates permeation through the mem-
brane. These mechanisms are frequently disturbed,
being responsible for the tendency of cells to migrate
and colonize distant organs. These processes are con-
trolled by various enzymes, including degrading pro-
teases, type IV collagenases and cathepsins [18].
Matrix metalloproteinase-9 (MMP-9) can degrade
major complexes of the extracellular matrix (ECM),
type IV collagen and gelatin, and therefore its activa-
tion is closely related to the invasive and metastatic
capacity of cancer cells [16]. Considerably higher
MMP-9 expression was found in stage II and III/IV
according to Bormann classification than in stage I
[28]. Zhang et al. [17] observed MMP-9 expression in
65.23% of gastric carcinoma patients, but found no
relationship with tumor size and location or patients'
gender. However, they observed a correlation between
MMP-9 expression and tumor cell proliferation, depth
of invasion, lymph node metastases or TNM stage of
gastric carcinoma. Additionally, they noted that MMP-
9 expression increased in advanced carcinoma as com-
pared to early stages. These results seem to indicate
that MMP-9 expression plays a key role in the pro-
gression of gastric carcinoma and can thus be used as
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Table 1. Expression of MMP9 and chosen clinical and pathological parameters in main mass of tumor and in lymph node metastasis.
*NS - no statistical significence
a marker of invasion [17]. We found the expression of
MMP-9 in approximately 42% of cases and like other
researchers we did not observe any relationship with
such parameters as patients' gender or tumor location.
Most frequently we found MMP-9 expression in
tumors of intestinal-type in Lauren's classification,
infiltrating the whole gastric wall, but contrary to some
researches, in our study no significant correlations
were noted. Similarly, in the case of cathepsin B, the
expression was most common in the intestinal type
tumors infiltrating the whole gastric wall, but no sta-
tistically significant correlations were observed. How-
ever, we noted a strong statistically significant associ-
ation between cathepsin B expression and lymph node
involvement, which is consistent with other literature
reports [29,30].  Cathepsin B expression is related to
the histological grade and TNM stage [29]. High
cathepsin B expression correlates with depth of inva-
sion in advanced rather than early (non-metastatic)
stages. These data seem to indicate a relationship
between gastric carcinoma malignancy and cathepsin
B expression [30]. The expression of cathepsins may
also correlate with the presence of distant metastases.
Higher levels of cathepsin B, cathepsin L and UPA
(urokinase-type plasminogen activator) have been
observed in samples from patients with metastases to
lymph nodes or liver, as compared to non-metastatic
patients. The above results may confirm the correla-
tion between the synthesis of cysteine and serine pro-
teases and the potential tumor invasion [9].
Moreover, we demonstrated a strong association
between MMP-9 expression and lymph node involve-
ment. Also other authors observed a correlation of
MMP-9 expression in gastric carcinoma with the pres-
ence of metastases in lymph nodes [23,17]. Endo et al.
[31] reported that the levels of MMP-2 and MMP-9 in
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Table 2. Expression of cathepsin B and chosen clinical and pathological parameters in main mass of tumor and in lymph node metastasis.
*NS - no statistical significence
the serum and plasma were found to correlate with
metastasis and invasion of gastric cancer. The expres-
sion of MMP-2 and MMP-9 has also been observed in
early gastric carcinoma, but not found to correlate with
lymph node metastasis or invasion depth [3,32]. How-
ever, Kabashima et al. [23] reported a statistically sig-
nificant correlation between MMP-9, but not MMP-2,
and lymph node involvement in IMGCs (intra mucos-
al gastric carcinoma). The activity of MMP-9 in the
degradation of the basement membrane was approxi-
mately 25 times higher than that of MMP-2. Therefore,
MMP-9 can be considered a more sensitive factor for
metastatic potential than MMP-2 [33,34]. 
The expression balance between MMP-9 and its
TIMP-1 inhibitor plays a central role in the metastatic
process. It has been found that the metastatic range in
gastric cancer decreases markedly in the presence of
MMP-9 and TIMP-1. This suggests that MMP-9 is
involved in metastasis promotion, while TIMP-1 inde-
pendently inhibits this process in gastric cancer [17].
It has been reported that gastric carcinomas of a
more aggressive phenotype show increased synthesis
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Fig. 1. Expression of MMP-9 in main
mass of tumor.
Fig. 2. Expression of cathepsin B in main
mass of tumor.
of proteases. Herszeny et al. [35] found considerably
higher values of cathepsin B in diffused gastric carci-
noma as compared to the intestinal type. Patients with
the scirrhus- infiltrate growth pattern (Borman typ IV)
also had  significantly high levels of cathepsin B, UPA
and PAI-1 (plasminogen activator inhibitor type-1
antigen). Considerably higher levels of proteases have
been observed in moderately- and low-differentiated
tumors as compared to the well-differentiated ones.
Moreover, it has been suggested that the increased
cathepsin B expression accompanied by fragmentation
of tumor-related laminin may play a role in tumor pro-
gression. A correlation has also been noted of cathep-
sin B expression with tumor stage and lymph node
involvement [26].
The analysis of the mean survival time revealed
that gastric cancer patients with high expression of
cathepsin B had shorter survival rates (9 months), as
compared to patients with poor or negative expression
(16 months). We found no statistically significant cor-
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Fig. 3. Correlation of MMP9 protein
expression in main mass of tumor with
survival of patients with advanced gas-
tric cancer.
Fig. 4. Correlation of cathepsin B pro-
tein expression in main mass of tumor
with survival of patients with advanced
gastric cancer.
relation between a 5-year postoperative survival and
tumor cathepsin B expression. However, as revealed
by literature data, strong positive staining for cathepsin
B correlates with more aggressive behavior of gastric
carcinoma, which affects the postoperative survival
and prognosis in patients after tumor resection [35,36]. 
Sier et al. [37] has reported that the expression
and activation of MMP-9 in cancer tissue has a prog-
nostic value for shorter survival time of gastric carci-
noma patients, irrespective of the main clinico-patho-
logical parameters. Also Zhang et al. [17] have
shown a significant relationship between MMP-9 and
TIMP-1 expression and postoperative survival time
of gastric carcinoma patients. They suggested that
patients with MMP-9 over-expression and with no
TIMP-1 expression had more aggressive tumor pro-
gression and shorter survival time [17]. We found a
correlation between high MMP-9 expression in main
mass of tumor and lymph node involvement. More-
over, patients with high expression of this protein had
a considerably longer survival time as compared to
the MMP-9 negative group (statistically insignificant
data).
Concluding, our results indicate that MMP-9  and
cathepsin B expression is associated with lymph node
involvement in advanced gastric carcinoma, but not
with postoperative survival time of patients. Addition-
ally, cathepsin B expression is correlated with depth of
invasion.
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